In the course of defining mutations causing Tay-Sachs disease (TSD) in non-Jewish patients and carriers from the British Isles, we identified a guanine to adenine change (also previously described) in the obligatory GT sequence of the donor splice site at the 5' end of intron 9 of the hexosaminidase a peptide gene. Of 24 unrelated mutant chromosomes from 20 non-Jewish subjects (15 TSD carriers, four TSD patients, and one TSD fetus), five had mutations common in the Ashkenazi Jewish community, and 10 had the intron 9 splice site mutation. This is an unexpected result considering the diverse origin of the population of the British Isles. This mutation was not found in 28 control UK subjects or 11 Jewish carriers of known TSD mutations. Before attempting detection of unknown mutations, non-Jewish TSD carriers from the British Isles should be screened for the intron 9 donor splice site mutation as well as those mutations which predominate in the Jewish community.
Tay-Sachs disease (TSD) is one of the GM2 gangliosidoses, a group of neurodegenerative disorders of autosomal recessive inheritance. In the 'classic' infantile form of TSD, onset of symptoms occurs at about 6 months and death by 4 years of age. The symptoms are caused by accumulation of the ganglioside GM2 in neur- onal cells owing to deficient activity of the lysosomal enzyme which metabolises it, 1-hexosaminidase A (hex A). ' The frequency of TSD carriers in the general population is approximately 1/200, but is much higher in certain ethnic groups (for example, 1/27 in Ashkenazi Jews), and carrier screening programmes involving assay of serum hex A have been implemented in order to reduce incidence of the disease.
Hex A is composed of a and peptide chains, coded for by genes on chromosomes 15 and 5, respectively; mutations in the a peptide (HEXA) gene are the cause of TSD. This gene has been cloned2' and several mutations causing TSD have been described. The first of these were found in ethnic groups having a high incidence of TSD, namely the FrenchCanadian population (nearly 3% of whom are carriers, predominantly of a 7-6 kb deletion),45 and the Ashkenazi Jews (3% of whom are TSD carriers, predominantly of a 4 base pair insertion in exon 116 and a mutation of the intron 12 donor splice site79). More recently, a phenylalanine deletion has been described in five out of eight obligate TSD carriers from the Moroccan Jewish population.'0 Many different mutations, all individually rare, have also been described in patients from low incidence populations, some of which have been reviewed by Neufeld."1
We have previously assessed the frequency of known TSD causing mutations in 41 UK Ashkenazi Jewish TSD carriers'2; 33 had the exon 11 insert mutation and eight had the intron 12 splice site mutation. In the present study we have attempted to identify the mutations in non-Jewish TSD patients and carriers from the UK and Eire using amplification by polymerase chain reaction (PCR)"3 and chemical mismatch detection'4'5 followed by direct sequencing'6 of amplified products. These techniques have already been used successfully to detect new mutations causing other genetic diseases, for example haemophilia A'7 and B'5 and Duchenne muscular dystrophy,'8 and more recently Tay-Sachs disease. 9 
Methods
The diagnosis of TSD, or carrier status, was established by enzyme assay of fibroblast samples, chorionic villi sample and/or serum and leucocyte samples using previously described methods.20 Genomic DNA of TSD patients, carriers, and 28 UK non-Jewish control subjects was extracted from EDTA blood, fibroblasts, or from cultured chorionic villi cells using established techniques.2' RNA was extracted from fibroblasts or EDTA blood using the acid-guanidinium thiocyanatephenol-chloroform method22 modified (by using sodium acetate at pH 5-2 instead of pH 4) to coprecipitate DNA with the RNA.
All of the TSD carriers (as defined by enzyme assay) were tested for the exon 11 insert and intron 12 donor splice site mutations (which predominate in Jewish TSD carriers) using methods described elsewhere'2; subjects negative for these were screened for unknown mutations using chemical mismatch detection. The HEXA gene was amplified from genomic DNA by PCR in nine sections from exon 2 to the 3' untranslated region with primers designed from the published cDNA sequence2 (sequences available on request) and synthesised using a PCR-mate DNA synthesiser (Applied Biosystems). Approximately 50 ng genomic DNA were subjected to PCR amplification in a 50 gil reaction volume containing 1 x PCR buffer (67 mmol/l Tris-HCl, pH 8-8, hydroxylamine.' 145 The regions of mutation or polymorphism indicated by any mismatch bands were sequenced directly'6 using the enzyme Sequenase (United States Biochemical Corporation). The mutation detected using the chemical mismatch method (on PCR products amplified with primers Hexa8F and Hexol OR) was screened for by sequencing or restriction enzyme digestion since it fortuitously destroys a MaeII cutting site. Purified PCR products (amplified using the primers Hexa9F and HexalOR) were digested with MaeII (Boehringer Mannheim Biochemica) in the buffer recommended by the manufacturer. Purified PCR products of a 736 base pair (bp) section of the factor IX gene'6 containing a control MaeII site were added to show whether digestion had been complete.
In order to determine effects of the mutation on mRNA, RNA extracted from fibroblasts of a TSD patient homozygous for the mutation and normal RNA was subjected to 'duplex' reverse transcription and PCR amplification. give a final volume of 50 RI. This mixture was then subjected to 23 cycles of PCR amplification, each cycle being one minute at 93'C, one minute at 65'C, and seven minutes at 72'C, lastly followed by five minutes at 72'C. Electrophoresis of 8 p1 of the reaction products was performed in a 1 % agarose (Ultrapure, Gibco-BRL) minigel with ethidium bromide. Reverse transcription and PCR amplification were also carried out with only one set of primers, specific for the HEXA gene (Hexa6F and region indicated by the 357 bp mismatch band was sequenced in the same eight subjects ( fig  2) . The first base of intron 9 was changed from guanine (G) to adenine (A) in those patients who have the mismatch band. All five subjects shown in fig 2 to have the mutation were heterozygous for it since they also had the normal G base at this position. The G to A mutation alters the obligatory GT of the intron 9 donor splice site. (The donor splice site is next to the 3' end of an exon, and is essential for 'splicing out' of introns to form the mRNA.)
Nineteen unrelated mutant chromosomes from 15 UK or Eire TSD carriers and patients who were negative for the common 'Jewish' mutations were tested for the intron 9 donor splice site mutation using sequencing or digestion with MaeII restriction enzyme or both; 10 were found to be positive ( Canadians45 and the Ashkenazi Jews.'9 The intron 9 donor splice site mutation described in this study, which has also been detected by Akli et al,19 appears to be very frequent among non-Jewish TSD patients and carriers from the British Isles. Of 19 unrelated chromosomes which had already been shown not to carry either of the two common 'Jewish' mutations, 53% were found to be positive for the intron 9 donor splice site mutation. This was an unexpected result since the population studied is not a genetic isolate; carriers of the mutation include people of English, Scottish, Welsh, and Irish origin.
The nature of the mutation itself indicates that it is highly likely to be the cause of disease, since it is a change in the first nucleotide of intron 9, the donor splice site. Splice sites are known to have invariant sequence24 (GT) within their consensus sequence, any change leading to incorrect splicing of the mRNA and the production of aberrant, unstable mRNA species. 25 This has already been shown to be the case for the intron 12 donor splice site mutation,26 causing TSD in the Ashkenazi Jewish community, an intron 5 donor splice site in a Tunisian TSD patient,27 and introns 2 and 4 donor splice site mutations in two French TSD patients. '9 The G to A change in the first base of intron 9 is also unlikely to be a polymorphism since (1) it was not found in 28 UK non-Jewish controls, (2) it was not found in 12 healthy Jewish carriers of known TSD mutations, and (3) if this change is simply a very frequent polymorphism then some non-TSD subjects could be expected to be homozygous; the only homozygotes found were two TSD patients (table 2) . The G to A change has occurred at a CpG dinucleotide, frequent sites of mutation owing to spontaneous deamination of methylcytosine to thymidine.28 Since this is a G to A change it must have arisen in the antisense strand (rather than the sense strand which would result in C to T).
We would speculate that mutation of the intron 9 donor splice site would cause exon 9 to be lost during mRNA splicing. However, the coding sequence would continue to be in frame so that the protein produced would not be severely truncated but simply reduced by 29 amino acids (those coded for by exon 9). Preliminary studies using duplex reverse transcription and PCR amplification of RNA of a patient homozygous for the mutation showed Of the 24 unrelated chromosomes tested in this study, the mutations of nine remain unknown; it will be interesting to see how many other mutations are present in the population. It seems unlikely that there will be one other very frequent mutation as in the Ashkenazim, as the population of the British Isles is very diverse in origin. The situation may resemble that of cystic fibrosis where there is one predominant mutation, AF508, which accounts for approximately 74% of UK cystic fibrosis carriers, and several other rare muta- 29 tions.
Carrier screening and prenatal diagnosis of Tay-Sachs disease can be done very effectively by enzyme assay of hex A.' Rapid detection of new mutations causing TSD using PCR amplification, chemical mismatch, and sequencing will be useful in confirmation of borderline diagnoses and the development of preimplantation diagnosis. The present work shows that TSD families from the non-Jewish population of the British Isles should be screened for the intron 9 donor splice mutation, as well as the mutations which predominate in the Ashkenazi Jewish community, before more intense studies are undertaken to delineate their mutations.
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